GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AbbVie ABBV · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

S&P 500

Compare

293.30

+0.68%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$61.16bn

FY2016FY2025

Net income

$4.23bn

FY2016FY2025

Free cash flow

$17.82bn

FY2016FY2025

Shareholders' equity

−$3.23bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$61.16bn$56.33bn$54.32bn$58.05bn$56.20bn$45.80bn$33.27bn$32.75bn$28.22bn$25.64bn
Gross profit$42.96bn$39.43bn$33.90bn$40.64bn$38.75bn$30.42bn$25.83bn$25.04bn$21.18bn$19.80bn
Research and development$9.10bn$12.79bn$7.67bn$6.51bn$8.05bn$7.75bn$6.79bn$10.75bn$5.33bn$4.58bn
Operating income$9.49bn$9.14bn$7.93bn$18.12bn$17.92bn$5.85bn$10.21bn$6.38bn$9.54bn$9.34bn
Net income$4.23bn$4.28bn$4.86bn$11.84bn$11.54bn$4.62bn$7.88bn$5.69bn$5.31bn$5.95bn
Diluted earnings per share2.382.412.746.666.492.595.313.843.313.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$133.96bn$135.16bn$134.71bn$138.81bn$146.53bn$150.56bn$89.11bn$59.35bn$70.79bn$66.10bn
Cash and short-term investments$5.26bn$5.55bn$12.82bn$9.23bn$9.83bn$8.48bn$39.92bn$8.06bn$9.79bn$6.42bn
Total liabilities$137.19bn$131.80bn$124.31bn$121.52bn$131.09bn$137.47bn$97.29bn$67.80bn$65.69bn$61.46bn
Debt$67.69bn$67.14bn$59.38bn$63.27bn$76.68bn$86.06bn$66.73bn$40.31bn$37.37bn$36.84bn
Shareholders' equity−$3.23bn$3.36bn$10.40bn$17.29bn$15.44bn$13.10bn−$8.17bn−$8.45bn$5.10bn$4.64bn
Shares outstanding1,774m1,773m1,772m1,778m1,778m1,781m1,485m1,481m1,602m1,623m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$19.03bn$18.81bn$22.84bn$24.94bn$22.78bn$17.59bn$13.32bn$13.43bn$9.96bn$7.04bn
Capital spending−$1.21bn−$974.0m−$777.0m−$695.0m−$787.0m−$798.0m−$552.0m−$638.0m−$529.0m−$479.0m
Free cash flow$17.82bn$17.83bn$22.06bn$24.25bn$21.99bn$16.79bn$12.77bn$12.79bn$9.43bn$6.56bn
Dividends paid−$11.66bn−$11.03bn−$10.54bn−$10.04bn−$9.26bn−$7.72bn−$6.37bn−$5.58bn−$4.11bn−$3.72bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$16.99bn$15.00bn$16.62bn$15.78bn$15.42bn$13.34bn$15.10bn$14.46bn
Gross profit$14.39bn$10.78bn$12.07bn$10.47bn$11.08bn$9.34bn$10.71bn$10.25bn
Operating income$6.72bn$4.73bn$5.81bn$1.45bn$4.89bn$3.73bn−$1.57bn$3.83bn
Net income$3.62bn$699.0m$1.82bn$186.0m$938.0m$1.29bn−$22.0m$1.56bn
Diluted earnings per share2.040.391.020.100.530.72-0.010.88
Cash from operations$3.44bn$3.83bn$5.22bn$7.02bn$5.15bn$1.64bn$7.05bn$5.45bn
Capital spending−$265.0m−$265.0m−$329.0m−$504.0m−$269.0m−$235.0m−$291.0m−$249.0m
Free cash flow$3.17bn$3.56bn$4.89bn$6.52bn$4.88bn$1.40bn$6.76bn$5.20bn
Total assets$135.13bn$136.46bn$133.96bn$133.90bn$137.18bn$136.16bn$135.16bn$143.42bn
Cash and short-term investments$6.57bn$9.39bn$5.26bn$5.67bn$6.47bn$5.18bn$5.55bn$7.29bn
Debt$70.82bn$72.86bn$67.50bn$68.74bn$70.48bn$69.89bn$67.14bn$71.08bn
Shareholders' equity−$5.93bn−$6.61bn−$3.23bn−$2.60bn−$138.0m$1.46bn$3.36bn$6.07bn

Financial ratios

Data as of 1 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin70.2%70.0%62.4%70.0%69.0%66.4%
Operating margin15.5%16.2%14.6%31.2%31.9%12.8%
Net margin6.9%7.6%9.0%20.4%20.5%10.1%
Return on equity-130.9%127.2%46.8%68.5%74.8%35.2%
Return on assets3.2%3.2%3.6%8.5%7.9%3.1%
Free cash flow yield4.5%4.4%5.2%5.6%5.2%4.0%
Revenue growth8.6%3.7%-6.4%3.3%22.7%37.7%
Earnings growth-1.2%-12.0%-58.9%2.5%150.0%-41.4%
Current ratio0.67x0.66x0.87x0.96x0.79x0.84x
Debt to equity-20.97x19.96x5.71x3.67x4.98x6.58x
Equity ratio-2.4%2.5%7.7%12.5%10.5%8.7%
Interest coverage3.28x3.25x3.57x8.12x7.40x2.38x
R&D as a share of sales14.9%22.7%14.1%11.2%14.3%16.9%
Buybacks as a share of market value-0.1%-0.1%0.3%0.0%0.2%-19.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.8%6.0%10.3%
Operating income-19.4%10.2%2.3%
Net income-29.1%-1.7%-1.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin70.1%68.3%68.1%70.9%
Operating margin15.9%19.4%20.6%23.5%
Net margin7.2%11.0%12.5%15.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings95.973.756.524.320.941.316.724.029.217.1
Price to sales6.65.65.15.04.34.24.04.25.54.0

Market value over time

30 Sept 2016 to 31 Aug 2026, in USD

$103.43bn$454.12bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return29%13%-5%23%26%16%5%-12%57%8%

Dividends and splits

Per share, in the currency the company pays

Paid for 13 years. Last went ex-dividend on 15 Oct 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year5.196.656.295.995.715.314.844.39

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.